^
1m
Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro. (PubMed, Cancer Drug Resist)
The ABCG2 inhibitor (fumitremorgin C) and P-gp inhibitor (valspodar) effectively blocked the transport mediated by ABCG2 and P-gp of rose bengal and BPD... In summary, our study provided new knowledge that temoporfin, talaporfin sodium, methylene blue, and indocyanine green are not substrates of ABCG2, P-gp, or MRP1...Rose bengal is a substrate of ABCG2, P-gp, and MRP1. The results presented here indicate ABC transporter substrate status as a possible cause for cellular resistance to photodynamic therapy with rose bengal, redaporfin, and BPD.
Preclinical • Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • ABCC1 (ATP Binding Cassette Subfamily C Member 1)
|
Foscan (temoporfin) • Litx (talaporfin)
5ms
Ultrasound-Activated PROTAC Prodrugs Overcome Immunosuppression to Actuate Efficient Deep-Tissue Sono-Immunotherapy in Orthotopic Pancreatic Tumor Mouse Models. (PubMed, Nano Lett)
This prodrug activation results in the degradation of the target protein BRD4, while simultaneously reversing the upregulation of PD-L1 expression associated with the SDT process. In the orthotopic mouse model of pancreatic tumors, NPCe6+PRO effectively suppressed tumor growth in conjunction with US stimulation.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRD4 (Bromodomain Containing 4)
|
Litx (talaporfin)
1year
Induction of ferroptosis by photodynamic therapy and enhancement of antitumor effect with ferroptosis inducers. (PubMed, J Gastroenterol)
This study found that the mechanism underlying TS-PDT-induced ferroptosis constitutes direct lipid peroxidation by the generated ROS, and the inhibition of system xc, and that the combination of a ferroptosis inducer with TS-PDT enhances the antitumor effect of TS-PDT. Our findings suggest that ferroptosis-inducing therapies combined with PDT may benefit cancer patients.
Journal
|
GPX4 (Glutathione Peroxidase 4)
|
sorafenib • erastin • RSL3 • Litx (talaporfin)
1year
Novel chlorin e-based conjugates of tyrosine kinase inhibitors: Synthesis and photobiological evaluation as potent photosensitizers for photodynamic therapy. (PubMed, Eur J Med Chem)
Since tyrosine kinase inhibitor (TKI) could reverse ABCG2-mediated drug-resistance, novel chlorin e-based conjugates of Dasatinib and Imatinib as photosensitizer (PS) were designed and synthesized. It could reduce efflux of intracellular PS by inhibiting ABCG2 in HepG2 cells, and localize in mitochondria, lysosomes, golgi and ER, resulting in higher cell apoptosis rate and ROS production than Talaporfin. Moreover, it could induce cell autophagy and block cell cycle in S phase, and significantly inhibit tumor growth and prolong survival time on BALB/c nude mice bearing HepG2 xenograft tumor to a greater extent than chlorin e. Consequently, compound 10b could be applied as a promising candidate PS due to its good water-solubility and stability, low drug-resistance, high quantum yield of O and excellent antitumor efficacy in vitro and in vivo.
Journal
|
ABCG2 (ATP Binding Cassette Subfamily G Member 2)
|
dasatinib • imatinib • Litx (talaporfin)
1year
Photosensitizers for Photodynamic Therapy of Brain Cancers-A Review. (PubMed, Brain Sci)
The most commonly used photosensitizers include 5-aminolevulinic acid for the enzymatic generation of protoporphyrin IX, Temoporfin-THPC, Photofrin, Hypericin and Talaporfin. An overview of all three generations of photosensitizers is presented. Along with an indication of the limitations of the treatment of brain tumors, intraoperative photodynamic therapy and its possibilities are described as an alternative therapeutic method.
Review • Journal
|
Foscan (temoporfin) • Litx (talaporfin) • Photofrin (porfimer sodium)
over1year
Clinical Impact of the Charlson Comorbidity Index on the Efficacy of Salvage Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer. (PubMed, Intern Med)
The rate of an L-CR (p=0.035) and the 2-year PFS (p=0.029) and OS (p=0.018) rates in the CCI ≥1 group were significantly lower than those in the CCI=0 group. Conclusion This study found that the CCI was negatively associated with the efficacy of salvage TS-PDT for esophageal cancer.
Journal
|
Litx (talaporfin)
over1year
Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives. (PubMed, Cancers (Basel))
Trastuzumab emtansine demonstrated higher antiproliferative activity in CCA cells expressing higher levels of HER2...Hematoporphyrin derivatives, temoporfin, phthalocyanine-4, talaporfin, and chlorine e6 derivatives have mainly been used clinically and preclinically in bile duct cancer...Future human and artificial intelligence collaboration has potential for overcoming challenges related to identifying universal CCA cell targets. This could pave the way for highly targeted therapies for CCA, such as ADC, PDT, and PIT.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • MUC1 (Mucin 1)
|
HER-2 expression
|
Kadcyla (ado-trastuzumab emtansine) • Foscan (temoporfin) • Litx (talaporfin)
over1year
SALVAGE ENDOSCOPIC THERAPY FOR CT1N0M0 LOCAL FAILURE AFTER CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: MULTICENTER RETROSPECTIVE STUDY (UEGW 2023)
Aims & This multicenter study aimed to clarify the short- and long-term outcomes of salvage endoscopic therapy (endoscopic resection [ER: EMR/ESD] and photodynamic therapy using Talaporfin Sodium [PDT]) for cT1N0M0 local failure after CRT/RT for ESCC, and to identify factors that influence the outcomes of salvage endoscopic therapy... Our results suggest that salvage endoscopic therapy including ER or PDT appears to be an effective treatment option for cT1N0M0 local failure after CRT/RT, regardless of clinical tumor depth, resulting in a certain number of patients achieving long-term survival without the primary disease and preserving their esophagus.
Retrospective data
|
Litx (talaporfin)
over1year
EFFICACY AND SAFETY OF PHOTODYNAMIC THERAPY USING AN ULTRA-THIN ENDOSCOPE FOR LOCAL FAILURE AFTER RADIOTHERAPY FOR ESOPHAGEAL CANCER IN PATIENTS WITH ESOPHAGEAL STRICTURE (UEGW 2023)
PDT using talaporfin sodium, second-generation photosensitizer, has shown acceptably high local complete response (L-CR) rate for local failure after CRT or RT... Comparing with PDT using CE, PDT using UTE for local failure after CRT/RT for ESCC are favorable and can be the promising therapeutic option for the patients without other treatment option. To improve the efficacy and reduce the esophageal stricture of UTE-PDT, several devices designed specifically for UTE should be further developed.
Clinical
|
Litx (talaporfin)
over1year
Novel Photodynamic Therapy for Esophageal Squamous Cell Carcinoma following Radiotherapy. (PubMed, Life (Basel))
Recently, owing to the emergence of second-generation photodynamic therapy (PDT) using talaporfin sodium, PDT can be performed with less phototoxicity and therefore has regained popularity in the treatment of ESCC...Even in patients with a Charlson comorbidity index score ≥ 3, the 2-year overall survival rates were 100%. In conclusion, PDT was an efficacious and a safe salvage treatment in patients with local residual or recurrent ESCC following RT or CRT.
Journal
|
Litx (talaporfin)
over1year
Thermosensitive nanocomposite components for combined photothermal-photodynamic therapy in liver cancer treatment. (PubMed, Colloids Surf B Biointerfaces)
Thermal induction and sequential irradiation with 808 nm and 664 nm lasers induced the aggregation of H-TiO @PDA@ICG@NPe6 @Lipo at the tumor site to generate hyperthermia and massive reactive oxygen species (ROS), resulting in decreased cell activity or even cell apoptosis and restrained growth of allograft tumors. These findings underscore the favorable effects of H-TiO @PDA@ICG@NPe6 @Lipo on the combined phototherapies and provide approaches for the development of nano-drugs in the context of liver cancer.
Journal
|
Litx (talaporfin)
over1year
ANTI-TUMOR IMMUNITY ENHANCEMENT BY PHOTODYNAMIC THERAPY WITH TALAPORFIN SODIUM AND ANTI-PROGRAMMED DEATH 1 ANTIBODY (DDW 2023)
Conclusion TS-PDT not only induced a direct killing effect on tumor cells, but also enhanced the anti-tumor immunity, and more, exhibited synergism with the anti-PD-1 antibody. Therefore, we believe that the combination of TS-PDT and anti-PD-1 antibody may be used to develop potential anti-tumor therapeutic strategies.
PD(L)-1 Biomarker • IO biomarker
|
HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
|
Litx (talaporfin)
2years
Photodynamic Therapy by Glucose Transporter 1-Selective Light Inactivation. (PubMed, ACS Omega)
Western blot analysis indicated that GLUT1 was not detected in cell lines treated with 10 μM 8 under light irradiation. Furthermore, 8 reduced the levels of epidermal growth factor receptor tyrosine kinase (EGFR), phospho-ERK (Y204), and GLUT1 without affecting ERK, α-tubulin, and PCNA protein levels, whereas talaporfin sodium, a clinically approved photosensitizer for PDT, nonspecifically reduced intracellular protein levels in HeLa cells, indicating that 8 has a GLUT1-specific inactivation ability and causes light-induced cytotoxicity by modulating the EGFR/MAPK signaling pathway.
Journal
|
PCNA (Proliferating cell nuclear antigen)
|
Litx (talaporfin)
almost3years
Preclinical • Journal
|
CRP (C-reactive protein)
|
bleomycin • Litx (talaporfin)
over3years
[VIRTUAL] Molecular characterization of BRAF(V600E) CRC in response to Src-targeted therapy in vitro (EACR 2021)
Modified expression of Src (overexpression and KO) in HT29 significantly regulates clonogenicity, proliferation and migration abilities. Src overexpression is responsible of the acquired resistance to Dasatinib and regulates several pathways that could be involved in the tumorigenesis of BRAF mutated CRC.
Preclinical
|
BRAF (B-raf proto-oncogene) • MAPK8 (Mitogen-activated protein kinase 8)
|
BRAF V600E • BRAF V600
|
dasatinib • Litx (talaporfin)
over3years
[VIRTUAL] Molecular characterization of BRAF(V600E) CRC in response to Src-targeted therapy in vitro (EACR 2021)
Modified expression of Src (overexpression and KO) in HT29 significantly regulates clonogenicity, proliferation and migration abilities. Src overexpression is responsible of the acquired resistance to Dasatinib and regulates several pathways that could be involved in the tumorigenesis of BRAF mutated CRC.
Preclinical
|
BRAF (B-raf proto-oncogene) • MAPK8 (Mitogen-activated protein kinase 8)
|
BRAF V600E • BRAF V600
|
dasatinib • Litx (talaporfin)
over3years
[VIRTUAL] Molecular characterization of BRAF(V600E) CRC in response to Src-targeted therapy in vitro (EACR 2021)
Modified expression of Src (overexpression and KO) in HT29 significantly regulates clonogenicity, proliferation and migration abilities. Src overexpression is responsible of the acquired resistance to Dasatinib and regulates several pathways that could be involved in the tumorigenesis of BRAF mutated CRC.
Preclinical
|
BRAF (B-raf proto-oncogene) • MAPK8 (Mitogen-activated protein kinase 8)
|
BRAF V600E • BRAF V600
|
dasatinib • Litx (talaporfin)
over3years
[VIRTUAL] Molecular characterization of BRAF(V600E) CRC in response to Src-targeted therapy in vitro (EACR 2021)
Modified expression of Src (overexpression and KO) in HT29 significantly regulates clonogenicity, proliferation and migration abilities. Src overexpression is responsible of the acquired resistance to Dasatinib and regulates several pathways that could be involved in the tumorigenesis of BRAF mutated CRC.
Preclinical
|
BRAF (B-raf proto-oncogene) • MAPK8 (Mitogen-activated protein kinase 8)
|
BRAF V600E • BRAF V600
|
dasatinib • Litx (talaporfin)
over3years
Tea polyphenol EGCG inhibited colorectal-cancer-cell proliferation and migration via downregulation of STAT3. (PubMed, Gastroenterol Rep (Oxf))
Further investigation by luciferase-reporter-activity assay showed that EGCG suppressed the promoter activity of STAT3 and downregulated the transcription of STAT3. Our study presents evidence on the anti-proliferation and anti-migration effects of EGCG against colorectal-cancer SW480, SW620, and LS411N cells by downregulating the expression of STAT3 and suggests that EGCG could be an effective and natural supplement for colon-cancer treatment.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CDH1 (Cadherin 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • VIM (Vimentin)
|
Litx (talaporfin)
4years
Spatiotemporal metabolic dynamics of the photosensitizer talaporfin sodium in carcinoma and sarcoma. (PubMed, Cancer Sci)
We also demonstrated that ATP is essential for the uptake of talaporfin and that activation of K-Ras is involved as a regulatory mechanism. These results provide new insights into the metabolism of talaporfin in cancer cells for the enhancement of PDT for carcinoma and sarcoma.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
Litx (talaporfin)
4years
Possible mechanism of heme oxygenase-1 expression in rat malignant meningioma KMY-J cells subjected to talaporfin sodium-mediated photodynamic therapy. (PubMed, Photodiagnosis Photodyn Ther)
Our findings indicate that TS-PDT may induce HO-1 expression via reactive oxygen species production and then HIF-1 pathway activation in KMY-J cells, and the HO-1 induction may cause attenuation of the therapeutic effect of TS-PDT.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • HMOX1 (Heme Oxygenase 1)
|
HIF1A expression • HMOX1 expression
|
Litx (talaporfin) • echinomycin
4years
In-Vitro and In-Silico Evaluations of Heterocyclic-Containing Diarylpentanoids as Bcl-2 Inhibitors Against LoVo Colorectal Cancer Cells. (PubMed, Molecules)
In the present study, we investigated the in-vitro anti-cancer potential of six diarylpentanoids against a panel of BRAF- and KRAS-mutated colorectal cancer cell lines including T84, SW620, LoVo, HT29, NCI-H508, RKO, and LS411N cells...Further molecular docking studies revealed that the bromophenyl moieties of 2e could interact with the Bcl-2 surface pocket through hydrophobic interaction, while the tetrahydro-4H-thiopyran-4-one fragment could form additional Pi-sulfur and Pi-alkyl interactions in the same binding site. In all, the present results suggest that 2e could be a potent lead that deserves further modification and investigation in the development of a new Bcl-2 inhibitor.
Preclinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS mutation • BRAF mutation
|
Litx (talaporfin)